




UK Regenerative Medicine Landscape

Milan World EXPO 2015

The UK is pioneering regenerative medicine, bringing together research and innovation to explore the possibility of replacing, engineering and regenerating human cells, tissues and organs, triggering the human body's own repairing mechanisms.

Regenerative medicine also offers the potential to change the course of chronic diseases, representing a new hope for many, by using stem cells to grow tissues and organs in the laboratory. Regenerative medicine will tackle the challenge of an ageing population, reduce healthcare costs by providing a cure or better management for chronic or hard to treat diseases, and reduce the time and cost of drug development.

In the UK, The Cell Therapy Catapult has been established to accelerate delivery of therapies to patients and will work with industry to deliver clinical trials, provide manufacturing expertise and infrastructure, access the NHS and clinical partners, and provide business and regulatory expertise.



Event Programme and Speaker Profiles

Chair: Keith Thompson CEO Cell Therapy Catapult

Keith will open the session and will outline the role of the Catapult and how the UK continues to support this critical industry.

Prof Anthony Hollander University of Liverpool

Professor Hollander spun out a Regenerative Medicine company Azellon in the Musculo skeletal space and will talk on his experiences of being both scientist and founder of a small Regenerative Medicine start-up.

Dr John Sinden CSO and Co-founder Reneuron,

Reneuron is one of the largest of the UK Regenerative Medicine companies and John will present on his experiences of establishing and growing a successful Regenerative Medicine company in the UK.

Prof James Shaw Freeman Hospital Newcastle

Professor Shaw led on the development of the technology to implant additional islet of Langerhans in Diabetes patients. This procedure is now funded under the NHS Specialist Commissioning services. Jim will discuss how he and his colleagues developed this new solution and embedded it within the Health service.

Prof Julie Daniels University College London and Moorfields Eye Hospital

Professor Daniels is working on limbal stem cells in corneal ophthalmology and was one of the first researchers to establish GMP facilities in academia. She will discuss the challenges of being at the forefront of research in this area

A panel session will follow the speaker presentations to provide an opportunity for interaction and Q&A.



Keith Thompson
CEO of The Cell Therapy Catapult

Before being named CEO in May 2012, Keith, was National Director of the Scottish National Blood Transfusion Service where he led on modernising the blood supply and expanding the service into cell therapy. Keith has also held various senior domestic and international leadership positions where he developed several bio-manufacturing businesses to become global players.



Professor Anthony Hollander
Head of the Institute of Integrative Biology and Professor of Stem Cell Biology at the University of Liverpool

Professor Anthony Hollander has over two decades of research experience in the fields of cartilage biology, osteoarthritis, stem cells and tissue engineering. In 2008, Professor Hollander and a team of scientists and surgeons successfully created and then transplanted the first tissue-engineered trachea (windpipe), using a patient's own stem cells. The bioengineered trachea immediately provided the patient with a normally functioning airway, thereby saving her life.



Dr. John Sinden
Scientific co-founder of ReNeuron

John has held post-doctoral appointments at Oxford University and the Institute of Psychiatry prior to joining the permanent staff of the Institute in 1987 and becoming Reader in Neurobiology in 1996. He is active in a number of professional, industry and academic committees in the sector, he has over 100 peer-reviewed publications and is lead inventor on many patent families or applications including ReNeuron's new stem cell exosomes therapeutic platform.



Professor James Shaw
Professor of Regenerative Medicine for Diabetes at Newcastle University and Honorary Physician at the Newcastle Diabetes Centre and Freeman Hospital

Following PhD completion as an MRC fellow with Kevin Docherty exploring gene and cell replacement therapy for diabetes, a Glaxo-Smith-Kline Senior Fellowship enabled James to move to Newcastle and join the world-acclaimed diabetes team there. In addition to setting up a translational research laboratory he has established a regional insulin pump service, is a member of the Newcastle pancreas transplant team and clinical lead for islet transplantation.



Professor Julie Daniels
Director of Cells for Sight Stem Cell Therapy Research Unit

Julie is a leader in translational research on the use of stem cells for repair of the human ocular surface. The Cells for Sight Team is aiming to understand the biology and therapeutic potential of stem cells. Other research areas include interrogation of the stem cell niche, including the role of Pax6 in ocular surface failure in aniridia and investigating the mechanisms of conjunctival scarring in order to develop therapeutic anti-scarring strategies.